HZNP - Horizon Therapeutics reports Q2 earnings miss; revises FY 2022 net sales and Adj.EBITDA guidance
- Horizon Therapeutics press release ( NASDAQ: HZNP ): Q2 Non-GAAP EPS of $1.07 misses by $0.26 .
- Revenue of $876.4M (+5.3% Y/Y) misses by $62.42M .
- Revises Full-Year 2022 Guidance : Full-Year 2022 Net Sales guidance of $3.53 Billion to $3.60 Billion vs. consensus of $3.96B, Full-Year 2022 Adjusted EBITDA guidance of $1.30 Billion to $1.35 Billion; Full-Year 2022 TEPEZZA Net Sales Percentage Growth in the High-Teens.
For further details see:
Horizon Therapeutics reports Q2 earnings miss; revises FY 2022 net sales and Adj.EBITDA guidance